MedTrace Logo

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 313

Last updated 2013-01-17

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.

Conditions

Interventions

DRUG

Davunetide

Davunetide Nasal Spray 30 mg BID IN 52 weeks

DRUG

Placebo

Placebo Nasal Spray BID IN 52 weeks

Sponsors & Collaborators

  • Allon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Adam Boxer, M.D., PhD. · Memory and Aging Center, University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01110720 on ClinicalTrials.gov